Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".

about

Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".

Item

http://www.wikidata.org/entity/Q52937933

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Response to the letter by Adam ...... FDG-PET in Hodgkin lymphoma".

@en

Response to the letter by Adam ...... FDG-PET in Hodgkin lymphoma".

@nl

type

Item

label

Response to the letter by Adam ...... FDG-PET in Hodgkin lymphoma".

@en

Response to the letter by Adam ...... FDG-PET in Hodgkin lymphoma".

@nl

prefLabel

Response to the letter by Adam ...... FDG-PET in Hodgkin lymphoma".

@en

Response to the letter by Adam ...... FDG-PET in Hodgkin lymphoma".

@nl

P1476

Response to the letter by Adam ...... t FDG-PET in Hodgkin lymphoma"

@en

P2093

Charles Mesguich

http://www.w3.org/2001/XMLSchema#string

Elif Hindié

http://www.w3.org/2001/XMLSchema#string

Krimo Bouabdallah

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy

Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Treatment of Hodgkin lymphoma: a 50-year perspective.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.

Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy.

P2888

s00259-017-3773-6

P304

1937-1939

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-017-3773-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Noel Jean Milpied

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28707119

http://www.w3.org/2001/XMLSchema#string